Skip to main content
Top
Published in: Journal of Neurology 1/2010

01-01-2010 | Original Communication

The relationship between health, disability and quality of life in Myasthenia Gravis: results from an Italian study

Authors: Matilde Leonardi, Alberto Raggi, Carlo Antozzi, Paolo Confalonieri, Lorenzo Maggi, Ferdinando Cornelio, Renato Mantegazza

Published in: Journal of Neurology | Issue 1/2010

Login to get access

Abstract

Myasthenia gravis (MG) produces long term disability and affects health-related quality of life (HRQoL). This paper reports the relationship between HRQoL and disability in a group of patients with MG. Adult patients with MG were consecutively enrolled at the Neurological Institute “Carlo Besta”. The World Health Organization Disability Assessment Schedule II (WHO-DAS II) and the Medical Outcome Survey 36-Item Short-Form Health Survey (SF-36) were employed, and non-parametric analysis (Spearman’s rank correlation and Mann–Whitney U test) performed. One hundred and two consecutive adult patients with MG (70 female; mean age 47.2, sd 15.7) were recruited. The majority of WHO-DAS II and SF-36 scales were significantly correlated; WHO-DAS II summary score correlated better with SF-36 Physical Composite Score (PCS), than with mental composite score (MCS). Significant differences are also reported between patients with different muscle involvement in PCS and WHO-DAS II scores, while no difference was observed in MCS. The impact of MG on disability and HRQoL increases consistently with the disease’s severity. Our study highlights that measurements of HRQoL and disability in patients with MG are correlated and sensitive enough to capture different clinical profiles’ features. They measure different clinical and psychosocial facets, therefore we recommend employing specific assessments both for quality of life and disability in public health and clinical research on myasthenia gravis.
Literature
1.
go back to reference Apolone G, Mosconi P (1998) The Italian SF-36 health survey: translation, validation and norming. J Clin Epidemiol 51:1025–1036CrossRefPubMed Apolone G, Mosconi P (1998) The Italian SF-36 health survey: translation, validation and norming. J Clin Epidemiol 51:1025–1036CrossRefPubMed
2.
go back to reference Burns TM, Conaway MR, Cutter GR, Sanders DB, Muscle Study Group (2008) Less is more, or almost as much: a 15-item quality of life instrument for myasthenia gravis. Muscle Nerve 38:957–963CrossRefPubMed Burns TM, Conaway MR, Cutter GR, Sanders DB, Muscle Study Group (2008) Less is more, or almost as much: a 15-item quality of life instrument for myasthenia gravis. Muscle Nerve 38:957–963CrossRefPubMed
3.
go back to reference Buist-Bouwman MA, De Graaf R, Vollebergh WA, Alonso J, Bruffaerts R, Ormel J (2006) Functional disability of mental disorders and comparison with physical disorders: a study among the general population of six European countries. Acta Psychiatr Scand 113:492–500CrossRefPubMed Buist-Bouwman MA, De Graaf R, Vollebergh WA, Alonso J, Bruffaerts R, Ormel J (2006) Functional disability of mental disorders and comparison with physical disorders: a study among the general population of six European countries. Acta Psychiatr Scand 113:492–500CrossRefPubMed
4.
go back to reference Chisolm TH, Abrams HB, McArdle R, Wilson RH, Doyle PJ (2005) The WHO-DAS II: psychometric properties in the measurement of functional health status in adults with acquired hearing loss. Trends Amplif 9:111–126CrossRefPubMed Chisolm TH, Abrams HB, McArdle R, Wilson RH, Doyle PJ (2005) The WHO-DAS II: psychometric properties in the measurement of functional health status in adults with acquired hearing loss. Trends Amplif 9:111–126CrossRefPubMed
5.
go back to reference Chopra PK, Couper JW, Herrman H (2004) The assessment of patients with long-term psychotic disorders: application of the WHO Disability Assessment Schedule II. Aust NZ J Psychiatry 38:753–759 Chopra PK, Couper JW, Herrman H (2004) The assessment of patients with long-term psychotic disorders: application of the WHO Disability Assessment Schedule II. Aust NZ J Psychiatry 38:753–759
6.
go back to reference Chwastiak LA, Von Korff M (2003) Disability in depression and back pain: evaluation of the World Health Organization Disability Assessment Schedule (WHO-DAS II) in a primary care setting. J Clin Epidemiol 54:507–514CrossRef Chwastiak LA, Von Korff M (2003) Disability in depression and back pain: evaluation of the World Health Organization Disability Assessment Schedule (WHO-DAS II) in a primary care setting. J Clin Epidemiol 54:507–514CrossRef
7.
go back to reference Conti-Fine BM, Milani M, Kaminski HJ (2006) Myasthenia gravis: past, present, and future. J Clin Invest 116:2843–2854CrossRefPubMed Conti-Fine BM, Milani M, Kaminski HJ (2006) Myasthenia gravis: past, present, and future. J Clin Invest 116:2843–2854CrossRefPubMed
8.
go back to reference D’Alessandro R, Casmiro M, Benassi G, Rinaldi R, Gamberoni G (1995) Reliable disability scale for myasthenia gravis sensitive to clinical changes. Acta Neurol Scand 92:77–82PubMedCrossRef D’Alessandro R, Casmiro M, Benassi G, Rinaldi R, Gamberoni G (1995) Reliable disability scale for myasthenia gravis sensitive to clinical changes. Acta Neurol Scand 92:77–82PubMedCrossRef
9.
go back to reference Garratt A, Schmidt L, Mackintosh A, Fitzpatrick R (2002) Quality of life measurement: bibliographic study of patient assessed health outcome measures. BMJ 324:1417CrossRefPubMed Garratt A, Schmidt L, Mackintosh A, Fitzpatrick R (2002) Quality of life measurement: bibliographic study of patient assessed health outcome measures. BMJ 324:1417CrossRefPubMed
10.
go back to reference Guy-Coichard C, Nguyen DT, Delorme T, Boureau F (2008) Pain in hereditary neuromuscular disorders and myasthenia gravis: a national survey of frequency, characteristics and impact. J Pain Symptom Manage 35:40–50CrossRefPubMed Guy-Coichard C, Nguyen DT, Delorme T, Boureau F (2008) Pain in hereditary neuromuscular disorders and myasthenia gravis: a national survey of frequency, characteristics and impact. J Pain Symptom Manage 35:40–50CrossRefPubMed
11.
go back to reference Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB (2000) Myasthenia gravis: recommendations for clinical research standards: Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55:16–23PubMed Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB (2000) Myasthenia gravis: recommendations for clinical research standards: Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55:16–23PubMed
12.
go back to reference Lavrnic D, Vujic A, Rakocevic-Stojanovic V, Stevic Z, Basta I, Pavlovic S, Trikic R, Apostolski S (2005) Cyclosporine in the treatment of myasthenia gravis. Acta Neurol Scand 111:247–252CrossRefPubMed Lavrnic D, Vujic A, Rakocevic-Stojanovic V, Stevic Z, Basta I, Pavlovic S, Trikic R, Apostolski S (2005) Cyclosporine in the treatment of myasthenia gravis. Acta Neurol Scand 111:247–252CrossRefPubMed
13.
go back to reference Leonardi M, Bickenbach J, Ustun TB, Kostanjsek N, Chatterji S, MHADIE consortium (2006) The definition of disability: what is in a name? Lancet 368:1219–1221CrossRefPubMed Leonardi M, Bickenbach J, Ustun TB, Kostanjsek N, Chatterji S, MHADIE consortium (2006) The definition of disability: what is in a name? Lancet 368:1219–1221CrossRefPubMed
14.
go back to reference Mantegazza R, Antozzi C, Peluchetti D, Sghirlanzoni A, Cornelio F (1988) Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis. J Neurol 235:449–453CrossRefPubMed Mantegazza R, Antozzi C, Peluchetti D, Sghirlanzoni A, Cornelio F (1988) Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis. J Neurol 235:449–453CrossRefPubMed
15.
go back to reference Mantegazza R, Baggi F, Antozzi C et al (2003) Myasthenia gravis (MG): epidemiological data and prognostic factors. Ann NY Acad Sci 998:413–423CrossRefPubMed Mantegazza R, Baggi F, Antozzi C et al (2003) Myasthenia gravis (MG): epidemiological data and prognostic factors. Ann NY Acad Sci 998:413–423CrossRefPubMed
16.
go back to reference Mullins LL, Carpentier MY, Paul RH, Sanders DB, the Muscle Study Group (2008) Disease-specific measure of quality of life for Myasthenia Gravis. Muscle Nerve 38:947–956CrossRefPubMed Mullins LL, Carpentier MY, Paul RH, Sanders DB, the Muscle Study Group (2008) Disease-specific measure of quality of life for Myasthenia Gravis. Muscle Nerve 38:947–956CrossRefPubMed
17.
go back to reference Padua L, Evoli A, Aprile I, Caliandro P, Mazza S, Padua R, Tonali P (2001) Health-related quality of life in patients with myasthenia gravis and the relationship between patient-oriented assessment and conventional measurements. Neurol Sci 22:363–369CrossRefPubMed Padua L, Evoli A, Aprile I, Caliandro P, Mazza S, Padua R, Tonali P (2001) Health-related quality of life in patients with myasthenia gravis and the relationship between patient-oriented assessment and conventional measurements. Neurol Sci 22:363–369CrossRefPubMed
18.
go back to reference Paul RH, Nash JM, Cohen RA, Gilchristh JM, Goldstein JM (2001) Quality of life and well-being of patients with Myasthenia Gravis. Muscle Nerve 24:512–516CrossRefPubMed Paul RH, Nash JM, Cohen RA, Gilchristh JM, Goldstein JM (2001) Quality of life and well-being of patients with Myasthenia Gravis. Muscle Nerve 24:512–516CrossRefPubMed
19.
go back to reference Rostedt A, Padua L, Stalberg EV (2006) Correlation between regional myasthenic weakness and mental aspects of quality of life. Eur J Neurol 13:191–193CrossRefPubMed Rostedt A, Padua L, Stalberg EV (2006) Correlation between regional myasthenic weakness and mental aspects of quality of life. Eur J Neurol 13:191–193CrossRefPubMed
20.
go back to reference Ustun TB (1999) WHO-DAS II field trials report 1998. WHO, Geneva Ustun TB (1999) WHO-DAS II field trials report 1998. WHO, Geneva
22.
go back to reference World Health Organization (2001) The International Classification of Functioning, Disability and Health-ICF. WHO, Geneva World Health Organization (2001) The International Classification of Functioning, Disability and Health-ICF. WHO, Geneva
Metadata
Title
The relationship between health, disability and quality of life in Myasthenia Gravis: results from an Italian study
Authors
Matilde Leonardi
Alberto Raggi
Carlo Antozzi
Paolo Confalonieri
Lorenzo Maggi
Ferdinando Cornelio
Renato Mantegazza
Publication date
01-01-2010
Publisher
D. Steinkopff-Verlag
Published in
Journal of Neurology / Issue 1/2010
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-009-5279-z

Other articles of this Issue 1/2010

Journal of Neurology 1/2010 Go to the issue